https://scholars.lib.ntu.edu.tw/handle/123456789/355014
標題: | Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7- methylenedioxyquinolln-4-one monosodium phosphate (CHM-I-P-Na) as a potent antitumor agent | 作者: | CHE-MING TENG | 公開日期: | 2010 | 卷: | 53 | 期: | 4 | 起(迄)頁: | 1616-1626 | 來源出版物: | Journal of Medicinal Chemistry | 摘要: | CHM-1 [2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one] (1) has a unique antitumor mechanism of action. However, because 1 has relatively low hydrophilicity, it was evaluated only via ip administration, which is not clinically acceptable. In this study, we synthesized the monosodium phosphate salt (CHM-1 -P-Na, 4) of 1 as a hydrophilic prodrug. Compound 4 was rapidly converted into 1 following iv and po administration and also possessed excellent antitumor activity in a SKOV-3 xenograft nude mice model. Compound 4 also had clear-cut pharmacological effects on enzymes related with tumor cells. Neither 4 nor 1 significantly affected, normal biological function in a safety pharmacology profiling study. Compound 1 caused apoptotic effects in breast carcinoma cells via accumulation of cyclin Bl, and importantly, the endogenous levels of the mitotic spindle checkpoint, proteins BubRl directly correlated with cellular response to microtubule disruption. With, excellent antitumor activity profiles, 4 is highly promising for development as an anticancer clinical trials candidate. ? 2010 American Chemical Society. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-77649222713&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/355014 |
DOI: | 10.1021/jm901292j | SDG/關鍵字: | 2 (2 fluorophenyl) 6,7 methylenedioxyquinolin 4 one; 2 (2 fluorophenyl) 6,7 methylenedioxyquinolin 4 one monosodium phosphate; antineoplastic agent; apoptotic protease activating factor 1; Bub1 related protein; cell cycle protein; colchicine; cyclin B1; doxorubicin; paclitaxel; unclassified drug; animal experiment; animal model; animal tissue; antineoplastic activity; apoptosis; article; breast carcinoma; cancer inhibition; cell cycle arrest; cell cycle G2 phase; drug blood level; drug effect; drug mechanism; drug safety; drug screening; drug synthesis; female; human; human cell; hydrophilicity; male; maximum plasma concentration; mitosis spindle; mouse; nonhuman; ovary cancer; protein expression; single drug dose; upregulation; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclin B1; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Male; Mice; Mice, Nude; Mitosis; Neoplasm Transplantation; Phosphoric Acid Esters; Prodrugs; Protein-Serine-Threonine Kinases; Quinolines; Radioligand Assay; Transplantation, Heterologous |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。